INTRODUCTION
The selection of genetically modified cells in human gene therapy is a methodological challenge when potency and safety are linked to the purity of cell products manufactured ex vivo. A major focus of ex vivo cell engineering involves hematopoietically derived cells, in particular T cells modified to express chimeric antigen receptors for redirected tumor recognition. Selection following transfection/transduction typically involves physical purification on the basis of flow cytometric cell sorting or immunomagnetic techniques. Although these methodologies have several advantages, such as the use of human-encoded markers of transduction, these methods require expensive infrastructure such as GMP-compliant clinical cell sorting facilities, and clinical-grade reagents such as conjugated monoclonal antibodies. Alternately, cell selection can be achieved by chemical means on the basis of expressing enzymes that confer resistance to cytotoxic selection drugs. Although a number of drugresistance enzymes have been employed for selection of genemodified cells, such as bacterial phosphotransferases that confer resistance to hygromycin, neomycin and zeocin, these selection enzymes and drugs have proven disadvantages including the immunogenicity of the xenogeneic enzymes and the lack of GMPgrade selection drugs. [1] [2] [3] [4] [5] Human selection enzyme systems would carry the advantage of limited immunogenicity and, if coupled with pharmaceutical selection drugs, excellent applicability in the setting of cGMPcompliant manufacturing. Several enzyme systems have been described that employ human enzymes capable of conferring resistance to cytotoxic chemotherapeutic drugs for human hematopoietic stem cell selection in vivo. 2, [6] [7] [8] [9] [10] The methyl guanine methyltransferase (MGMT) mutein can render cells resistant to the alkylator drug temozolomide when administered in combination with O6-benzylguanine (O 6 -BG). [11] [12] [13] Although in vivo selection of gene-modified hematopoietic stem cells is achieved with this approach, it is not readily transferable to in vitro selection, nor is a genotoxic alkylator drug such as temolozomide a favorable agent for this purpose. In an effort to circumvent these challenges, we sought to develop a drugselection platform that uses a human-resistance enzyme and a non-genotoxic lymphotoxic pharmaceutical anti-metabolite drug. Other desirable features of the system include a small transgene footprint for the incorporation into gene-transfer vectors, a rapid mechanism of action for culling non-transduced cells from culture, and a high-expression threshold of the resistance gene such that linked therapeutic transgenes are also expressed at high levels following selection. Accordingly, we focused on the adaptation of mutant human dihydrofolate reductase (DHFR) constructs that confer resistance to lymphotoxic concentrations of MTX. [14] [15] [16] [17] In the present study, we evaluate the utility of a huDHFR FS 
RESULTS AND DISCUSSION
We first sought to define the minimum in vitro concentrations of MTX that render activated proliferating human T cells non-viable. Using Jurkat T cells, dose-viability response curves were generated at MTX concentrations up to 0.1 mM. As described previously, MTX acts through competitive binding with the dihydrofolate-binding site, which inhibits the ability of DHFR to convert dihydrofolate to tetrahydrofolate, resulting in inhibition of purine biosynthesis, and consequently, cell death of activated proliferating lymphocytes. 18 We identified a threshold MTX concentration of 0.05 mM that rendered cultured Jurkat T cells non-viable (Figure 1a ), a level consistent with the previous observations of MTX cytotoxicity against hematopoietically derived cells in culture. 14, 15, 19 Therefore, in all subsequent experiments, X0.05 mM MTX was used to examine DHFR FS -mediated rescue of primary human T cell viability and proliferation.
Mutagenesis of the DHFR coding sequence at codon positions 22 and 31 has been reported to result in a mutant DHFR (DHFR FS ) that retains 2.3% of its catalytic activity while exhibiting a 478-fold resistance to MTX inhibition. 14, 20 To determine whether huDHFR FS expressed from a human EF1-a promoter results in MTX resistance to concentrations of drug in excess of 0.05 mM, Jurkat cells were electroporated with a huDHFR FS -containing plasmid (Figure 1b ) then selected in media supplemented with 0.05 mM MTX for 7 days. Selected cells were then assayed for their susceptibility to cytocidal concentrations of MTX by re-plating in increasing concentrations (0-0.25 mM) of MTX. After 8 days of culture in these conditions, transfected/MTX-selected Jurkat cells were found to have expanded 101 ± 2.0-fold in 0.05 mM MTX (Figure 1c ). In this culture system, huDHFR FS expressing Jurkat cells retained viability with diminished proliferative activity in concentrations of MTX up to 0.25 mM. This is in contrast to mocktransfected/non-selected cells, which were rendered non-viable in 0.05 mM MTX (Figure 1a ). These data demonstrate that the huDHFR FS transgene expressed in Jurkat T cells confers resistance to otherwise cytocidal concentrations of MTX in vitro.
We next sought to incorporate the huDHFR FS -MTX selection system into our third generation SIN lentiviral vector system, and design trifunctional transgene constructs that place our CD19CAR and huEGFRt in frame with huDHFR FS , each separated by a T2A ribosomal skip linker (Figure 2a) . [21] [22] [23] As proof of concept, IL-2-dependent murine CTLL-2 T cells were first transduced with this CD19CAR:huEGFRt:huDHFR FS lentiviral vector and evaluated for To further delineate the range of MTX concentrations that could be tolerated by selected CTLL-2 cells, transduced cells selected in 0.1 mM MTX for 8 days were re-plated in a range of MTX concentrations (up to 0.75 mM). We observed 97-105-fold expansion of viable transduced cells at MTX concentrations up to 0.25 mM, which is equivalent to the fold expansion of nontransduced control CTLL-2 in the absence of MTX (Figure 2e ). In addition, these cells continued to expand and maintain at least 67% viability in MTX concentrations of 0.5 and 0.75 mM (that is, 29-fold-and 10-fold expansion over 8 days, respectively). These data clearly demonstrate that, as seen with huDHFR FS -transfected Jurkat cells, CTLL-2 cells transduced to express huDHFR FS in combination with two other functional transgenes acquire resistance to high concentrations (up to 0.75 mM) of MTX.
We next sought to define the utility of this selection system in the context of selecting primary human central memory T cells (T CM ), following CD19CAR:huEGFRt:huDHFR FS lentiviral vector transduction. Purified CD62L þ CD45RO þ healthy donor peripheral blood T CM were used in these experiments due to the capacity of expanded T cell products derived from these precursors to engraft, persist and re-populate memory T cell niches following adoptive transfer. 23, 24 Following activation of purified T CM using anti-CD3/CD28 Dynal beads, 50 U ml À 1 rhuIL-2 and 0.5 ng ml (Figure 3a) . Transduced T cells maintained a viability of 77.2±1.8% after 10 days MTX selection at X0.05 mM and the yield of selected cells was 1.7-6.2% of the number of viable cells at the initiation of selection (Figure 3a) . Flow cytometric evaluation of transduced T cells after 10 days in culture with varying concentrations of MTX revealed significant MTX-mediated enrichment of transgene-expressing cells up to 70-76% CD19CAR þ and 87-89% huEGFRt þ upon culture in X0.05 mM MTX from pre-selection levels of 17.9% and 28% percent, respectively (Figure 3b) . Comparison of the frequency of CD19CAR þ /huEGFRt þ expression at day 6 vs day 10 of MTX selection revealed the progressive enrichment of MTXresistant transgene expressing T cells over time (Figure 3c ). Of note, while these cells were predominately CD4 þ (Figure 4a ), comparable levels of expansion and MTX-mediated selection were observed with transduced CD8 þ T CM -derived cells (Supplementary Figure S1) . Furthermore, when a direct comparison between MTX-mediated selection and EGFRt-based immunomagnetic selection was performed with these same cells, the total yields of transgene þ cells were found to be comparable, if not better when using MTX (Supplementary Figure S2) . There also appears to be some flexibility in the timing of MTX addition to cultures, as addition of MTX on either day 0, day 4 or day 8 during an 18-day expansion of transduced cells resulted in fold expansion and transgene expression that only differed by 10-20% (Supplementary Figure S3) . Together these data support the utility of the huDHFR FS /MTX strategy for selecting gene-modified T cells in vitro.
We next sought to quantitate the level of MTX resistance of these expanded selected T CM after an additional round of expansion using OKT3 and irradiated feeder cells. 23, 25 The nontransduced (that is, unselected) cells and the transduced cells initially selected in 0.1 mM MTX exhibited similar expansion in the absence of MTX (Figure 3d ). In contrast, upon re-plating in escalating concentrations of MTX on day 8 of their second expansion cycle, the transduced MTX-selected cells exhibited retention of viability (480%) and proliferative activity (48.5-fold expansion after re-introduction of MTX) in MTX at concentrations up to 0.1 mM, while non-transduced T cells did not expand at any of the tested MTX concentrations (Figure 3d ). In addition, this second cycle of MTX exposure resulted in further selection of transgene þ cells (that is, 490% transgene positive in X0.025 mM MTX) (Figure 3e ). These data document the utility of the MTX/huDHFR FS system for purifying primary human T CM -derived T cells following lentiviral transduction and expansion to clinically relevant cell doses for adoptive therapy trials.
The effect of huDFHR FS expression and MTX selection on skewing the phenotype and function of primary human T CM is unknown. Accordingly, we examined the phenotype of our MTXselected CD19CAR:huEGFRt:huDHFR FS T CM lines and mock transduced non-selected control counterparts on the basis of surface expression of CD4, CD8, CD28, CD62L, TCRab, CD127 and CD45 (Figure 4a) . Expression of each of these T cell markers was equivalent to that observed on non-transduced, and on transduced but non-MTX-selected controls. Functionally, we tested selected and control lines for CD19CAR redirected cytolytic activity in 4-hour chromium-release assays against CD19 þ SupB15 and lymphoblastoid cell line (LCL) targets. MTX selection of transduced cells significantly increased the CD19CAR redirected cytolytic potency over that of their transduced non-selected counterparts (Figure 4b) . Furthermore, this cytolytic activity of the selected T cells was not affected by the addition to culture of 0.1 mM MTX during the assay. CD19CAR regulated activation of these T cells for cytokine secretion (IL-2, IFN-g, TNF-a, GM-CSF) in the supernatants of mixed lymphocyte-tumor cultures were augmented in cells selected in MTX, and not altered by the presence of 0.1 mM MTX during the assay (Figure 4c ). These data indicate that the functional profile of CD19CAR redirected T CM -derived effector cells is enriched by virtue of selection in MTX using culture methods that are currently employed in cell manufacture for human adoptive therapy trials. Overall, given our success with this platform in T cells, it will now be important to continue to compare our DHFR FS -mediated strategy to other cellular enrichment systems including those that utilize alternate DHFR mutants. 14, 20 On the basis of the in vitro analysis presented here, we speculate that the expression of DHFR FS by in vitro MTX selected T cells may be sufficient to render cells resistant to MTX administered to patients after adoptive transfer. MTX is an active drug against a variety of CD19 þ hematologic malignancies and the ability to use concombinant MTX chemotherapy with CD19-specific T cells may affect additive or synergistic anti-tumor effects. Additional potential attributes of this system unique to the crossover use of MTX in vitro and in vivo include the ability of MTX administration to induce lymphopenia and reinforce transgene expression with the potential outcome of the selective homeostatic cytokine-driven engraftment of transferred T cells over the repopulating repertoire of endogenous T cells. Of potential benefit, human drug-resistant genes such as huDHFR FS are also generally thought to be of limited immunogenicity as compared with other non-human transgene drug-selection strategies (that is, hygromycin, neomycin); 4, 5 however, the immunogenic potential of this DHFR muteins needs to be further investigated. Furthermore, when MTX is converted to polyglutamate derivatives within the cytosol, it reduces drug efflux, as well as enhances binding to endogenous target enzymes such as DHFR, 26 thus potentially enhancing its potency as a selection drug. This is the first study to demonstrate the feasibility of DHFR FSmediated in vitro enrichment of therapeutic (that is, CAR þ ) primary human T cells with MTX. DHFR FS -expressing Jurkat, CTLL-2 and primary human T cells consistently were resistant to the cytocidal effects of MTX at concentrations ranging from 0.025-0.25 mM in vitro. Such MTX concentrations are achievable in vivo and are clinically relevant, in that levels of 0.1-1 mM MTX have been detected in patients after administration of low doses of MTX (10-500 mg m À 2 ). 26 Furthermore, Zaharko et al. 26, 27 have shown that low-dose continuous MTX infusion in mice (1 mg h À 1 ) produced a sustained plasma concentration of 0.01 mM, and was sufficient to block cellular thymidylate synthesis. 26, 27 Thus, we are currently performing studies in animal models to assess the huDHFR FS /MTX-mediated selection of CAR þ T cells in vivo.
MATERIALS AND METHODS

Plasmid and lentiviral vector
The DHFR FS _ pcDNA3.1( À ) plasmid was generated by creating two point mutations in the wild-type human DHFR enzyme through site-directed mutagenesis (DHFR FS ; L22F/F31S) and ligated into pcDNA3.1( À ). The CD19CAR-T2A-EGFRt-T2A-DHFR FS _epHIV7 lentiviral vector was generated by cloning the cDNA encoding (a) CD19-specific chimeric antigen receptor; 21 14 The cDNA encoding the CD19CAR:huEGFRt:huDHFR FS was then incorporated into the lentiviral vector packaging plasmid epHIV-7 under control of human EF-1a promoter for production of the lentiviral vector. The correct assembly of the transgenes was verified with DNA sequence analysis. All DNA constructs and construction-associated PCR primer sequences are available upon request.
Cell lines and maintenance
Jurkat cells (Human T lymphoblast-like cell line), SupB15 leukemia, CTLL-2 cells (mouse T-cell line) and K562 cell lines were purchased from American Type Culture Collection (ATCC) and maintained according to the ATCC guidelines. EBV-transformed LCL, that expressed OKT3 (LCL-OKT3) cells were cultured as previously described. 25, 27 Human peripheral blood mononuclear cells were isolated from healthy donors with the approval of Institutional Review Board (#09025) of the City of Hope National Medical Center (COHNMC), as described. 23 Methotrexate selection of gene-modified T cells M Jonnalagadda et al cell isolation, stimulation, expansion (rapid expansion method; REM) and lentiviral-mediated transduction were done as described. 23 In vitro selection of gene-modified T cells
The MTX (Parenta Pharmaceuticals, PA, USA) concentration required for in vitro selection of gene-modified T cells was determined by doseresponse curve. Briefly, the selection was initiated on day 8 of REM stimulation cycle by plating 0.8 Â 10 6 transduced primary human T cells in 24-well tissue culture plates or 0.4 Â 10 6 transduced CTLL-2 or Jurkat T cells and cultured for 8-10 days at the increased concentrations of MTX. As controls, non-transduced T cells were plated with equal cell number. The total viable cell number and percentage of viable cells were enumerated by Guava Personal Cell Analysis (Guava Technologies, Hayward, CA, USA) method. The working concentrations of MTX were diluted in PBS. Transduced T cells were immunomagnetically selected for EGFRt expression with cetuximab as previously described. 23 
Flow cytometry
Cell surface phenotype was analyzed with fluorochrome-conjugated streptavidin and antibodies specific for CD4, CD8, CD28, TCRab, CD62L, CD45, and CD127 and isotype controls (BD Biosciences). Biotinylated antihuman Fc-specific mAb was purchased from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA, USA) PE-conjugated anti-Biotin was purchased from Miltenyi Biotec (Auburn, CA, USA). The generation of biotinylated-cetuximab has been previously described. 23 Stained cells were analyzed by FACScalibur, and the percentage of cells in a region of analysis were calculated using FCS Express V3 (De Novo Software).
Chromium-release assays
The cytolytic activity of T cells was determined by 4-h chromium-release assay (CRA) as previously described. 30 Measurement of cytokine production T cells (5 Â 10 4 ) were co-cultured overnight with 5 Â 10 4 SupB15, LCL-OKT3, LCL or K562 in 96-well tissue culture plates. Supernatants were measured by cytometric bead array assay using a bioplex human cytokine panel (Bio-Rad Laboratories, Hercules, CA, USA), according to the manufacturer's instructions.
Statistical analysis
Data are expressed as mean±s.d. Student's two-tailed t-test was used to evaluate the significance of differences between experimental groups for CRA and bioplex by using Graphpad prism (San Diego, CA, USA). Total viable cell numbers, percentage of viable cells between non-transduced and transduced cells were analyzed using repeated one-way analysis of variance by R program (http://www.r-project.org/). An effect is considered to be statistically significant when the P-value is o0.05. 
